LP6 Stock Overview
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Livzon Pharmaceutical Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥3.00 |
| 52 Week High | CN¥3.32 |
| 52 Week Low | CN¥2.54 |
| Beta | 0.25 |
| 1 Month Change | -2.60% |
| 3 Month Change | 3.45% |
| 1 Year Change | -6.25% |
| 3 Year Change | -17.58% |
| 5 Year Change | 25.81% |
| Change since IPO | 97.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| LP6 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 4.2% | -3.3% | -1.5% |
| 1Y | -6.3% | -30.8% | 0.9% |
Return vs Industry: LP6 exceeded the German Pharmaceuticals industry which returned -31.3% over the past year.
Return vs Market: LP6 underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| LP6 volatility | |
|---|---|
| LP6 Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LP6 has not had significant price volatility in the past 3 months.
Volatility Over Time: LP6's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 8,933 | Yanggang Tang | www.livzon.com.cn |
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers drug preparation products, including Ilaprazole enteric coated tablets to treat duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection to treat endometriosis, hysteromyoma, premenopausal breast and prostate cancer, and central precocious puberty; and Urofollitropin for injection to treat anovulation and sufferers. It also provides Perospirone hydrochloride tablets to treat schizophrenia; Shenqi Fuzheng Injection to treat weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for treating lung and stomach cancer; anti-viral granules used for clearing heat, eliminating dampness, cooling blood, and detoxifying to treat upper respiratory tract infection and influenza; Tocilizumab injection to treat rheumatoid arthritis; and Recombinant SARSCoV-2 fusion protein vaccine used to prevent diseases caused by SARS-CoV-2 infection.
Livzon Pharmaceutical Group Inc. Fundamentals Summary
| LP6 fundamental statistics | |
|---|---|
| Market cap | €3.96b |
| Earnings (TTM) | €253.57m |
| Revenue (TTM) | €1.61b |
17.8x
P/E Ratio2.8x
P/S RatioIs LP6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LP6 income statement (TTM) | |
|---|---|
| Revenue | CN¥12.43b |
| Cost of Revenue | CN¥4.77b |
| Gross Profit | CN¥7.66b |
| Other Expenses | CN¥5.70b |
| Earnings | CN¥1.95b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 23, 2024
| Earnings per share (EPS) | 2.12 |
| Gross Margin | 61.61% |
| Net Profit Margin | 15.72% |
| Debt/Equity Ratio | 27.9% |
How did LP6 perform over the long term?
See historical performance and comparison